ArticleCancer medicine2023

Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.

Wenzhe Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.